tetano
Editor, Senior Moderator
J Med Cases
. 2024 Dec;15(12):367-370.
doi: 10.14740/jmc4307. Epub 2024 Oct 30. New Onset of Type 1 Diabetes Mellitus Post-COVID-19 Vaccine
Khaled H Aburisheh[SUP] 1 [/SUP], Hamza M K Enabi[SUP] 2 [/SUP], Nora A Alodah[SUP] 2 [/SUP], Bassam H Alotary[SUP] 2 [/SUP], Linah A Algheryafi[SUP] 2 [/SUP], Ayman M Almairi[SUP] 2 [/SUP], Amani A Aldhewaila[SUP] 1 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased morbidity and mortality worldwide. Coronavirus disease 2019 (COVID-19) vaccines have shown high efficacy in preventing the infection but with many possible side effects such as hyperglycemia. New-onset diabetes mellitus (DM) and severe metabolic complications have been reported post-vaccination. Here we report a 45-year-old woman who came to the hospital complaining of polyurea, polydipsia, and weight loss 3 weeks after the first activation dose of COVID-19 vaccine. Her hemoglobin A1c (HbA1c) upon presentation was 9% without any prior history of DM. She was diagnosed with type 1 diabetes mellitus (T1DM), as the anti-glutamic acid decarboxylase (GAD) antibody was positive and complicated during follow-up with diabetic ketoacidosis (DKA). This is the first case in Saudi Arabia suggesting that the COVID-19 RNA-based vaccines might cause new onset of T1DM, complicated by late DKA.
Keywords: COVID-19; Hyperglycemia; SARS-CoV-2; Type 1 diabetes mellitus; mRNA vaccine.
. 2024 Dec;15(12):367-370.
doi: 10.14740/jmc4307. Epub 2024 Oct 30. New Onset of Type 1 Diabetes Mellitus Post-COVID-19 Vaccine
Khaled H Aburisheh[SUP] 1 [/SUP], Hamza M K Enabi[SUP] 2 [/SUP], Nora A Alodah[SUP] 2 [/SUP], Bassam H Alotary[SUP] 2 [/SUP], Linah A Algheryafi[SUP] 2 [/SUP], Ayman M Almairi[SUP] 2 [/SUP], Amani A Aldhewaila[SUP] 1 [/SUP]
Affiliations
- PMID: 39610907
- PMCID: PMC11602176
- DOI: 10.14740/jmc4307
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased morbidity and mortality worldwide. Coronavirus disease 2019 (COVID-19) vaccines have shown high efficacy in preventing the infection but with many possible side effects such as hyperglycemia. New-onset diabetes mellitus (DM) and severe metabolic complications have been reported post-vaccination. Here we report a 45-year-old woman who came to the hospital complaining of polyurea, polydipsia, and weight loss 3 weeks after the first activation dose of COVID-19 vaccine. Her hemoglobin A1c (HbA1c) upon presentation was 9% without any prior history of DM. She was diagnosed with type 1 diabetes mellitus (T1DM), as the anti-glutamic acid decarboxylase (GAD) antibody was positive and complicated during follow-up with diabetic ketoacidosis (DKA). This is the first case in Saudi Arabia suggesting that the COVID-19 RNA-based vaccines might cause new onset of T1DM, complicated by late DKA.
Keywords: COVID-19; Hyperglycemia; SARS-CoV-2; Type 1 diabetes mellitus; mRNA vaccine.